{"pmid":32416321,"title":"Patients with diabetes are at higher risk for severe illness from COVID-19.","text":["Patients with diabetes are at higher risk for severe illness from COVID-19.","It is currently uncertain whether people with diabetes are at higher risk of severe illness from coronavirus disease 2019 (COVID-19). We found that diabetes was associated with an approximately 4-fold increased risk of having severe/critical COVID-19 illness. This association was independent of age, sex, obesity, hypertension and smoking. These findings highlight the urgent need for a multidisciplinary team-based approach to management of this patient population.","Diabetes Metab","Targher, Giovanni","Mantovani, Alessandro","Wang, Xiao-Bo","Yan, Hua-Dong","Sun, Qing-Feng","Pan, Ke-Hua","Byrne, Christopher D","Zheng, Kenneth I","Chen, Yong-Ping","Eslam, Mohammed","George, Jacob","Zheng, Ming-Hua","32416321"],"abstract":["It is currently uncertain whether people with diabetes are at higher risk of severe illness from coronavirus disease 2019 (COVID-19). We found that diabetes was associated with an approximately 4-fold increased risk of having severe/critical COVID-19 illness. This association was independent of age, sex, obesity, hypertension and smoking. These findings highlight the urgent need for a multidisciplinary team-based approach to management of this patient population."],"journal":"Diabetes Metab","authors":["Targher, Giovanni","Mantovani, Alessandro","Wang, Xiao-Bo","Yan, Hua-Dong","Sun, Qing-Feng","Pan, Ke-Hua","Byrne, Christopher D","Zheng, Kenneth I","Chen, Yong-Ping","Eslam, Mohammed","George, Jacob","Zheng, Ming-Hua"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416321","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.diabet.2020.05.001","keywords":["covid-19","diabetes","virus infection"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666994545854775296,"score":9.490897,"similar":[{"pmid":32472662,"title":"COVID-19 and diabetes: Is there enough evidence?","text":["COVID-19 and diabetes: Is there enough evidence?","The pandemic of COVID-19, a disease caused by a novel coronavirus SARS-CoV-2, is associated with significant morbidity and mortality. Recent data showed that hypertension, diabetes mellitus, cardiovascular diseases, and chronic obstructive pulmonary disease were the most prevalent comorbidities in COVID-19 patients. Additionally, data indicate that hypertension, diabetes, and cardiovascular diseases are important risk factors for progression and unfavorable outcome in COVID-19 patients. There is only limited amount of data regarding follow-up of these patients, and they provided conflicting results. The main limitation is a small number of participants and particularly those who experienced primary composite outcome (admission in intensive care unit, use of mechanical ventilation, or death). Additionally, the limited number of patients was essential obstacle for performing analysis that would include many confounding factors such as advanced age, smoking status, and obesity and potentially change conclusion. So far, there is no study that demonstrated independent predictive value of diabetes on mortality in COVID-19 patients, but there are many speculations about the association between diabetes and susceptibility to novel coronavirus, as well as its impact on progression and prognosis of COVID-19. The aim of this review article was to summarize the current knowledge about the relationship between diabetes and COVID-19 and its role in outcome in these patients.","J Clin Hypertens (Greenwich)","Tadic, Marijana","Cuspidi, Cesare","Sala, Carla","32472662"],"abstract":["The pandemic of COVID-19, a disease caused by a novel coronavirus SARS-CoV-2, is associated with significant morbidity and mortality. Recent data showed that hypertension, diabetes mellitus, cardiovascular diseases, and chronic obstructive pulmonary disease were the most prevalent comorbidities in COVID-19 patients. Additionally, data indicate that hypertension, diabetes, and cardiovascular diseases are important risk factors for progression and unfavorable outcome in COVID-19 patients. There is only limited amount of data regarding follow-up of these patients, and they provided conflicting results. The main limitation is a small number of participants and particularly those who experienced primary composite outcome (admission in intensive care unit, use of mechanical ventilation, or death). Additionally, the limited number of patients was essential obstacle for performing analysis that would include many confounding factors such as advanced age, smoking status, and obesity and potentially change conclusion. So far, there is no study that demonstrated independent predictive value of diabetes on mortality in COVID-19 patients, but there are many speculations about the association between diabetes and susceptibility to novel coronavirus, as well as its impact on progression and prognosis of COVID-19. The aim of this review article was to summarize the current knowledge about the relationship between diabetes and COVID-19 and its role in outcome in these patients."],"journal":"J Clin Hypertens (Greenwich)","authors":["Tadic, Marijana","Cuspidi, Cesare","Sala, Carla"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472662","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/jch.13912","keywords":["covid-19","coronavirus","diabetes","outcome","risk factors"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668255193282641920,"score":145.19206},{"pmid":32422233,"title":"Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx, New York.","text":["Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx, New York.","BACKGROUND & AIMS: New York is the current epicenter of Coronavirus disease 2019 (COVID-19) pandemic. The underrepresented minorities, where the prevalence of obesity is higher, appear to be affected disproportionately. Our objectives were to assess the characteristics and early outcomes of patients hospitalized with COVID-19 in the Bronx and investigate whether obesity is associated with worse outcomes independently from age, gender and other comorbidities. METHODS: This retrospective study included the first 200 patients admitted to a tertiary medical center with COVID-19. The electronic medical records were reviewed at least three weeks after admission. The primary endpoint was in-hospital mortality. RESULTS: 200 patients were included (female sex: 102, African American: 102). The median BMI was 30 kg/m(2). The median age was 64 years. Hypertension (76%), hyperlipidemia (46.2%), and diabetes (39.5%) were the three most common comorbidities. Fever (86%), cough (76.5%), and dyspnea (68%) were the three most common symptoms. 24% died during hospitalization (BMI<25 kg/m(2): 31.6%, BMI 25-34 kg/m(2): 17.2%, BMI>/=35 kg/m(2): 34.8%, p= 0.03). Increasing age (analyzed in quartiles), male sex, BMI>/=35 kg/m(2) (reference: BMI 25-34 kg/m(2)), heart failure, CAD, and CKD or ESRD were found to have a significant univariate association with mortality. The multivariate analysis demonstrated that BMI>/=35 kg/m(2) (reference: BMI 25-34 kg/m(2), OR: 3.78; 95% CI: 1.45 - 9.83; p=0.006), male sex (OR: 2.74; 95% CI: 1.25 - 5.98; p=0.011) and increasing age (analyzed in quartiles, OR: 1.73; 95% CI: 1.13 - 2.63; p=0.011) were independently associated with higher in-hospital mortality. Similarly, age, male sex, BMI>/=35 kg/m(2) and current or prior smoking were significant predictors for increasing oxygenation requirements in the multivariate analysis, while male sex, age and BMI>/=35 kg/m(2) were significant predictors in the multivariate analysis for the outcome of intubation. CONCLUSIONS: In this cohort of hospitalized patients with COVID-19 in a minority-predominant population, severe obesity, increasing age, and male sex were independently associated with higher in-hospital mortality and in general worse in-hospital outcomes.","Metabolism","Palaiodimos, Leonidas","Kokkinidis, Damianos G","Li, Weijia","Karamanis, Dimitrios","Ognibene, Jennifer","Arora, Shitij","Southern, William N","Mantzoros, Christos S","32422233"],"abstract":["BACKGROUND & AIMS: New York is the current epicenter of Coronavirus disease 2019 (COVID-19) pandemic. The underrepresented minorities, where the prevalence of obesity is higher, appear to be affected disproportionately. Our objectives were to assess the characteristics and early outcomes of patients hospitalized with COVID-19 in the Bronx and investigate whether obesity is associated with worse outcomes independently from age, gender and other comorbidities. METHODS: This retrospective study included the first 200 patients admitted to a tertiary medical center with COVID-19. The electronic medical records were reviewed at least three weeks after admission. The primary endpoint was in-hospital mortality. RESULTS: 200 patients were included (female sex: 102, African American: 102). The median BMI was 30 kg/m(2). The median age was 64 years. Hypertension (76%), hyperlipidemia (46.2%), and diabetes (39.5%) were the three most common comorbidities. Fever (86%), cough (76.5%), and dyspnea (68%) were the three most common symptoms. 24% died during hospitalization (BMI<25 kg/m(2): 31.6%, BMI 25-34 kg/m(2): 17.2%, BMI>/=35 kg/m(2): 34.8%, p= 0.03). Increasing age (analyzed in quartiles), male sex, BMI>/=35 kg/m(2) (reference: BMI 25-34 kg/m(2)), heart failure, CAD, and CKD or ESRD were found to have a significant univariate association with mortality. The multivariate analysis demonstrated that BMI>/=35 kg/m(2) (reference: BMI 25-34 kg/m(2), OR: 3.78; 95% CI: 1.45 - 9.83; p=0.006), male sex (OR: 2.74; 95% CI: 1.25 - 5.98; p=0.011) and increasing age (analyzed in quartiles, OR: 1.73; 95% CI: 1.13 - 2.63; p=0.011) were independently associated with higher in-hospital mortality. Similarly, age, male sex, BMI>/=35 kg/m(2) and current or prior smoking were significant predictors for increasing oxygenation requirements in the multivariate analysis, while male sex, age and BMI>/=35 kg/m(2) were significant predictors in the multivariate analysis for the outcome of intubation. CONCLUSIONS: In this cohort of hospitalized patients with COVID-19 in a minority-predominant population, severe obesity, increasing age, and male sex were independently associated with higher in-hospital mortality and in general worse in-hospital outcomes."],"journal":"Metabolism","authors":["Palaiodimos, Leonidas","Kokkinidis, Damianos G","Li, Weijia","Karamanis, Dimitrios","Ognibene, Jennifer","Arora, Shitij","Southern, William N","Mantzoros, Christos S"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422233","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.metabol.2020.154262","keywords":["bronx","covid-19","new york","sars-cov-2","coronavirus","mortality","obesity","pandemic","risk factor"],"locations":["New York","Bronx","African American","hyperlipidemia","Bronx","New York"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667159284600799232,"score":145.07011},{"pmid":32436622,"title":"Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients.","text":["Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients.","BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) has attracted increasing worldwide attention. While diabetes is known to aggravate COVID-19 severity, it is not known whether non-diabetic patients with metabolic dysfunction are also more prone to more severe disease. We investigated the association of metabolic associated fatty liver disease (MAFLD) to COVID-19 severity in non-diabetic patients. METHODS: The study cohort comprised 65 patients with- (i.e. cases) and 65 patients without MAFLD (i.e. controls). Each case was randomly matched with one control by sex (1:1) and age (+/-5 years). The association between presence of MAFLD (as exposure) and COVID-19 severity (as the outcome) was assessed by binary logistic regression analysis. RESULTS: In non-diabetic patients with COVID-19, the presence of MAFLD was associated with a 4-fold increased risk of severe COVID-19; the risk increased with increasing numbers of metabolic risk factors. The association with COVID-19 severity persisted after adjusting for age, sex and coexisting morbid conditions. CONCLUSIONS: Health care professionals caring for non-diabetic patients with COVID-19 should be cognizant of the increased likelihood of severe COVID-19 in patients with metabolic associated fatty liver disease.","J Gastroenterol Hepatol","Gao, Feng","Zheng, Kenneth I","Wang, Xiao-Bo","Yan, Hua-Dong","Sun, Qing-Feng","Pan, Ke-Hua","Wang, Ting-Yao","Chen, Yong-Ping","George, Jacob","Zheng, Ming-Hua","32436622"],"abstract":["BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) has attracted increasing worldwide attention. While diabetes is known to aggravate COVID-19 severity, it is not known whether non-diabetic patients with metabolic dysfunction are also more prone to more severe disease. We investigated the association of metabolic associated fatty liver disease (MAFLD) to COVID-19 severity in non-diabetic patients. METHODS: The study cohort comprised 65 patients with- (i.e. cases) and 65 patients without MAFLD (i.e. controls). Each case was randomly matched with one control by sex (1:1) and age (+/-5 years). The association between presence of MAFLD (as exposure) and COVID-19 severity (as the outcome) was assessed by binary logistic regression analysis. RESULTS: In non-diabetic patients with COVID-19, the presence of MAFLD was associated with a 4-fold increased risk of severe COVID-19; the risk increased with increasing numbers of metabolic risk factors. The association with COVID-19 severity persisted after adjusting for age, sex and coexisting morbid conditions. CONCLUSIONS: Health care professionals caring for non-diabetic patients with COVID-19 should be cognizant of the increased likelihood of severe COVID-19 in patients with metabolic associated fatty liver disease."],"journal":"J Gastroenterol Hepatol","authors":["Gao, Feng","Zheng, Kenneth I","Wang, Xiao-Bo","Yan, Hua-Dong","Sun, Qing-Feng","Pan, Ke-Hua","Wang, Ting-Yao","Chen, Yong-Ping","George, Jacob","Zheng, Ming-Hua"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436622","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jgh.15112","keywords":["covid-19","metabolic associated fatty liver disease","non-diabetes"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667521393682546688,"score":139.61403},{"pmid":32320741,"pmcid":"PMC7166301","title":"Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.","text":["Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.","BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020. Patients with metabolic associated fatty liver disease (MAFLD) are often obese and have additional metabolic risk factors which may aggravate the severity of respiratory diseases and of COVID-19. This study aims to investigate the association between MAFLD and COVID-19 severity. METHODS: 214 patients with laboratory-confirmed COVID-19 aged between 18 and 75years from three hospitals in Wenzhou, China were consecutively enrolled. Sixty-six patients with MAFLD were included in the final analysis. COVID-19 was diagnosed as a positive result by high-throughput sequencing or real-time reverse transcriptase-polymerase chain reaction assay of oropharyngeal swab specimens. COVID-19 severity was assessed during hospitalization and classified as severe and non-severe based on the current management guideline. All patients were screened for fatty liver by computed tomography and subsequently diagnosed as MAFLD according to a recent set of consensus diagnostic criteria. Obesity was defined as BMI >25kg/m(2). RESULTS: The presence of obesity in MAFLD patients was associated with a~6-fold increased risk of severe COVID-19 illness (unadjusted-OR 5.77, 95% CI 1.19-27.91, p=.029). Notably, this association with obesity and COVID-19 severity remained significant (adjusted-OR 6.32, 95% CI 1.16-34.54, p=.033) even after adjusting for age, sex, smoking, diabetes, hypertension, and dyslipidaemia. CONCLUSIONS: Our data demonstrate that the risk of obesity to COVID-19 severity is greater in those with, than those without MAFLD.","Metabolism","Zheng, Kenneth I","Gao, Feng","Wang, Xiao-Bo","Sun, Qing-Feng","Pan, Ke-Hua","Wang, Ting-Yao","Ma, Hong-Lei","Liu, Wen-Yue","George, Jacob","Zheng, Ming-Hua","32320741"],"abstract":["BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020. Patients with metabolic associated fatty liver disease (MAFLD) are often obese and have additional metabolic risk factors which may aggravate the severity of respiratory diseases and of COVID-19. This study aims to investigate the association between MAFLD and COVID-19 severity. METHODS: 214 patients with laboratory-confirmed COVID-19 aged between 18 and 75years from three hospitals in Wenzhou, China were consecutively enrolled. Sixty-six patients with MAFLD were included in the final analysis. COVID-19 was diagnosed as a positive result by high-throughput sequencing or real-time reverse transcriptase-polymerase chain reaction assay of oropharyngeal swab specimens. COVID-19 severity was assessed during hospitalization and classified as severe and non-severe based on the current management guideline. All patients were screened for fatty liver by computed tomography and subsequently diagnosed as MAFLD according to a recent set of consensus diagnostic criteria. Obesity was defined as BMI >25kg/m(2). RESULTS: The presence of obesity in MAFLD patients was associated with a~6-fold increased risk of severe COVID-19 illness (unadjusted-OR 5.77, 95% CI 1.19-27.91, p=.029). Notably, this association with obesity and COVID-19 severity remained significant (adjusted-OR 6.32, 95% CI 1.16-34.54, p=.033) even after adjusting for age, sex, smoking, diabetes, hypertension, and dyslipidaemia. CONCLUSIONS: Our data demonstrate that the risk of obesity to COVID-19 severity is greater in those with, than those without MAFLD."],"journal":"Metabolism","authors":["Zheng, Kenneth I","Gao, Feng","Wang, Xiao-Bo","Sun, Qing-Feng","Pan, Ke-Hua","Wang, Ting-Yao","Ma, Hong-Lei","Liu, Wen-Yue","George, Jacob","Zheng, Ming-Hua"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320741","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.metabol.2020.154244","keywords":["covid-19","mafld","obesity","sars-cov-2"],"locations":["obese","Wenzhou","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138493696344068,"score":133.7565},{"pmid":32474598,"title":"Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico.","text":["Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico.","BACKGROUND: The SARS-CoV-2 outbreak poses challenge to healthcare systems due to high complication rates in patients with cardiometabolic diseases. Here, we identify risk factors and propose a clinical score to predict COVID-19 lethality, including specific factors for diabetes and obesity and its role in improving risk prediction. METHODS: We obtained data of confirmed and negative COVID-19 cases and their demographic and health characteristics from the General Directorate of Epidemiology of Mexican Ministry of Health. We investigated specific risk factors associated to COVID-19 positivity and mortality and explored the impact of diabetes and obesity on modifying COVID-19 related lethality. Finally, we built a clinical score to predict COVID-19 lethality. RESULTS: Among 177,133 subjects at May 18th, 2020, we observed 51,633 subjects with SARS-CoV-2 and 5,332 deaths. Risk factors for lethality in COVID-19 include early-onset diabetes, obesity, COPD, advanced age, hypertension, immunosuppression, and CKD; we observed that obesity mediates 49.5% of the effect of diabetes on COVID-19 lethality. Early-onset diabetes conferred an increased risk of hospitalization and obesity conferred an increased risk for ICU admission and intubation. Our predictive score for COVID-19 lethality included age >/=65 years, diabetes, early-onset diabetes, obesity, age <40 years, CKD, hypertension, and immunosuppression and significantly discriminates lethal from non-lethal COVID-19 cases (c-statistic=0.823). RESULTS: Here, we propose a mechanistic approach to evaluate risk for complications and lethality attributable to COVID-19 considering the effect of obesity and diabetes in Mexico. Our score offers a clinical tool for quick determination of high-risk susceptibility patients in a first contact scenario.","J Clin Endocrinol Metab","Bello-Chavolla, Omar Yaxmehen","Bahena-Lopez, Jessica Paola","Antonio-Villa, Neftali Eduardo","Vargas-Vazquez, Arsenio","Gonzalez-Diaz, Armando","Marquez-Salinas, Alejandro","Fermin-Martinez, Carlos A","Naveja, J Jesus","Aguilar-Salinas, Carlos A","32474598"],"abstract":["BACKGROUND: The SARS-CoV-2 outbreak poses challenge to healthcare systems due to high complication rates in patients with cardiometabolic diseases. Here, we identify risk factors and propose a clinical score to predict COVID-19 lethality, including specific factors for diabetes and obesity and its role in improving risk prediction. METHODS: We obtained data of confirmed and negative COVID-19 cases and their demographic and health characteristics from the General Directorate of Epidemiology of Mexican Ministry of Health. We investigated specific risk factors associated to COVID-19 positivity and mortality and explored the impact of diabetes and obesity on modifying COVID-19 related lethality. Finally, we built a clinical score to predict COVID-19 lethality. RESULTS: Among 177,133 subjects at May 18th, 2020, we observed 51,633 subjects with SARS-CoV-2 and 5,332 deaths. Risk factors for lethality in COVID-19 include early-onset diabetes, obesity, COPD, advanced age, hypertension, immunosuppression, and CKD; we observed that obesity mediates 49.5% of the effect of diabetes on COVID-19 lethality. Early-onset diabetes conferred an increased risk of hospitalization and obesity conferred an increased risk for ICU admission and intubation. Our predictive score for COVID-19 lethality included age >/=65 years, diabetes, early-onset diabetes, obesity, age <40 years, CKD, hypertension, and immunosuppression and significantly discriminates lethal from non-lethal COVID-19 cases (c-statistic=0.823). RESULTS: Here, we propose a mechanistic approach to evaluate risk for complications and lethality attributable to COVID-19 considering the effect of obesity and diabetes in Mexico. Our score offers a clinical tool for quick determination of high-risk susceptibility patients in a first contact scenario."],"journal":"J Clin Endocrinol Metab","authors":["Bello-Chavolla, Omar Yaxmehen","Bahena-Lopez, Jessica Paola","Antonio-Villa, Neftali Eduardo","Vargas-Vazquez, Arsenio","Gonzalez-Diaz, Armando","Marquez-Salinas, Alejandro","Fermin-Martinez, Carlos A","Naveja, J Jesus","Aguilar-Salinas, Carlos A"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474598","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1210/clinem/dgaa346","keywords":["covid-19","diabetes","lethality","mexico","obesity","sars-cov-2"],"locations":["Mexico","Mexico"],"countries":["Mexico"],"countries_codes":["MEX|Mexico"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668341932586172416,"score":130.92853}]}